AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.
This post first appeared in The New York Times – Business. Read the original article.How a Drug Company Made $114 Billion by Gaming the U.S. Patent System
The New York Times – Business:
Written by
in
